Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to C difficile.
This article was originally published by HCPLive®. It has been lightly edited.
Several antibiotics commonly administered to ICU patients may be associated with a greater risk of Clostridioides difficile infection and related adverse drug reactions, according to a study published in Pharmaceuticals.1
Of more than 100,000 suspected adverse drug reaction reports registered in EudraVigilance, most related to C difficile were associated with ciprofloxacin, ceftriaxone, and piperacillin/tazobactam, highlighting the importance of antibiotic surveillance and monitoring programs to reduce the risk of adverse events.
“There is a heterogeneous relationship between antibiotic use in the intensive care unit (ICU) and C difficile," the authors wrote. "The most used antibiotics in the ICU are non-selective in their action, disrupting gut microbiota and creating an environment in which C difficile thrives.”
The CDC estimated C difficile to cause almost half a million infections in the US each year, noting patients are 7 to 10 times more likely to develop it when taking antibiotics or during the month thereafter. Understanding which antibiotics are associated with a greater risk of C difficile is essential for developing safe and effective treatment regimens not likely to cause adverse drug reactions.2
To assess the risk of C difficile associated with the use of commonly administered antibiotics, investigators retrospectively reviewed C difficile Individual Case Safety Reports submitted to EudraVigilance spontaneously reported as adverse drug reactions associated with the use of ceftriaxone, colistimethate, ciprofloxacin, gentamicin, linezolid, meropenem, and piperacillin/tazobactam.1 Total adverse drug reactions and total C difficile cases for these 7 drugs were centralized and used to calculate the proportion of adverse drug reactions related to C difficile.
Antibiotics
Image credit: neirfy - stock.adobe.com
Between January 1, 2003, and August 7, 2023, a total of 119,123 adverse drug reactions were reported in EudraVigilance. The greatest proportions of adverse drug reactions related to C difficile were observed for ciprofloxacin (31%), ceftriaxone (29%), piperacillin/tazobactam (14%), and linezolid (12%). Although the number of reports for C difficile was greatest for ciprofloxacin, both meropenem and piperacillin/tazobactam had the greatest proportion of adverse drug reactions related to C difficile from the total Individual Case Safety Reports (3%).
A retrospective analysis of Individual Case Safety Reports in EudraVigilance between January 1, 2003, and December 31, 2022, showed the greatest average reports per year for ciprofloxacin (40.5; 95% CI, 27.6–53.4) and piperacillin/tazobactam (25.3; 95% CI, 13.6–36.9), and the lowest for linezolid (2.8; 95% CI, 1.8–3.8) and colistimethate (1.5; 95% CI, 0.7–2.3). For meropenem and gentamicin, the average number of reports per year was 13.6 (95% CI, 7.6–19.5) and 4.9 (95% CI, 3.3–6.5), respectively.
Further analysis of reports with unfavorable outcomes showed the greatest frequency of an unfavorable outcome was observed for ciprofloxacin (21.8%) and meropenem (20.5%). Conversely, the lowest frequency of an unfavorable outcome was calculated for gentamicin (11.8%) and ceftriaxone (13.2%). Also, the greatest frequency of fatal adverse drug reactions was seen in colistimethate (15%), meropenem (14%), and ciprofloxacin (13.6%).
Investigators performed a disproportionality analysis to evaluate the probability of reporting C difficle related to these 7 antibiotics compared to amikacin, ceftazidime, clindamycin, imipenem/cilastatin, and levofloxacin; results showed all studied antibiotics had a lower reporting probability when compared to clindamycin.
“There is a pressing need to promote responsible antibiotic usage to prevent adverse events and preserve the efficacy of these valuable medications," the investigators concluded. "An increasing rate of severe forms of C difficile imposes the necessity to carry out surveillance and monitoring programs for the consumption of antibiotics. Implementing standardized laboratory tests to characterize C difficile's nature accurately is also essential.”
References:
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More